Drug interactions
Epirubicin + Trastuzumab deruxtecan
Severity: Major
Epirubicin and Trastuzumab deruxtecan: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Trastuzumab-based therapy can cause cardiomyopathy and left ventricular dysfunction, and the risk is highest when given with anthracyclines. Epirubicin adds its own dose-related cardiotoxicity, and trastuzumab deruxtecan also carries risk of interstitial lung disease and myelosuppression.
What this interaction means in plain words
Epirubicin and Trastuzumab deruxtecan can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Epirubicin belongs to Oncology; Trastuzumab deruxtecan belongs to Oncology.
Why it happens
Additive cardiotoxicity from HER2 inhibition and anthracycline-induced myocardial injury.
What to do
Avoid concurrent use when possible and keep the interval between agents as long as practical. Check left ventricular ejection fraction before and during treatment.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Epirubicin and Trastuzumab deruxtecan, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Epirubicin
- Adenovirus types 4 and 7 live + Epirubicin Contraindicated
- Belatacept + Epirubicin Major
- Cimetidine + Epirubicin Major
- Deferiprone + Epirubicin Major
- Dengue vaccine + Epirubicin Major
- Epirubicin + Etrasimod Major
Other interactions of Trastuzumab deruxtecan
Frequently asked questions
Can I take Epirubicin with Trastuzumab deruxtecan?
MediHelp rates the interaction as major. Epirubicin and Trastuzumab deruxtecan can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Trastuzumab-based therapy can cause cardiomyopathy and left ventricular dysfunction, and the risk is highest when given with anthracyclines. Epirubicin adds its own dose-related cardiotoxicity, and trastuzumab deruxtecan also carries risk of interstitial lung disease and myelosuppression.
How serious is the interaction between Epirubicin and Trastuzumab deruxtecan?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid concurrent use when possible and keep the interval between agents as long as practical. Check left ventricular ejection fraction before and during treatment.
What other medicines interact with Epirubicin?
MediHelp also lists interactions of Epirubicin with, for example, Adenovirus types 4 and 7 live, Belatacept, Cimetidine. The full list is on the Epirubicin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
